Jupiter Neurosciences Appoints New Directors, CEO & CSO

Ticker: JUNS · Form: 8-K · Filed: 2024-12-20T00:00:00.000Z

Sentiment: neutral

Topics: management-change, board-election, executive-compensation

TL;DR

Jupiter Neurosciences brings in new blood for the board and exec team, including CEO & CSO.

AI Summary

Jupiter Neurosciences, Inc. announced on December 17, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. David M. Goldenberg and Mr. David M. S. Johnson, to its Board of Directors. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Dr. David M. Goldenberg, and Chief Scientific Officer, Dr. David M. S. Johnson, effective December 17, 2024.

Why It Matters

The appointment of new directors and executive leadership changes can signal a shift in company strategy or operational focus, potentially impacting future performance and shareholder value.

Risk Assessment

Risk Level: medium — Changes in board composition and executive leadership can introduce uncertainty regarding future strategy and execution.

Key Players & Entities

FAQ

Who were the new directors appointed to Jupiter Neurosciences' Board?

Dr. David M. Goldenberg and Mr. David M. S. Johnson were elected as new directors to the Board of Directors.

What positions do the new directors hold in the company?

Dr. David M. Goldenberg was appointed as Chief Executive Officer, and Mr. David M. S. Johnson was appointed as Chief Scientific Officer.

When were these appointments and agreements effective?

The appointments and new employment agreements were effective as of December 17, 2024.

What is the former name of Jupiter Neurosciences, Inc.?

The former name of Jupiter Neurosciences, Inc. was Jupiter Orphan Therapeutics, Inc.

What is the principal executive office address of Jupiter Neurosciences, Inc.?

The principal executive offices are located at 1001 North US HWY 1, Suite 504, Jupiter, FL 33477.

From the Filing

0001493152-24-050881.txt : 20241220 0001493152-24-050881.hdr.sgml : 20241220 20241220070015 ACCESSION NUMBER: 0001493152-24-050881 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20241217 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241220 DATE AS OF CHANGE: 20241220 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JUPITER NEUROSCIENCES, INC. CENTRAL INDEX KEY: 0001679628 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 474828381 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41265 FILM NUMBER: 241565083 BUSINESS ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 BUSINESS PHONE: (561) 406-6154 MAIL ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 FORMER COMPANY: FORMER CONFORMED NAME: Jupiter Orphan Therapeutics, Inc. DATE OF NAME CHANGE: 20160713 8-K 1 form8-k.htm false 0001679628 0001679628 2024-12-17 2024-12-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): December 17, 2024   JUPITER NEUROSCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter)   Delaware   001-41265   47-4828381 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   1001 North US HWY 1 , Suite 504 Jupiter , FL   33477 (Address of Principal Executive Offices)   (Zip Code)   (561) 406-6154 (Registrant’s Telephone Number, Including Area Code)   N/A (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock   JUNS   Nasdaq Capital Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   As previously disclosed, on December 31, 2022, Jupiter Neurosciences, Inc. (the “Company”) entered into a Master Services Agreement (the “MSA”) with Titan Advisory Services LLC (“Titan”) pursuant to which Titan agreed to provide certain services to the Company. The MSA provide

View on Read The Filing